Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis

被引:12
|
作者
Clerc, Olivier F. [1 ,2 ]
Datar, Yesh [1 ,2 ]
Cuddy, Sarah A. M. [2 ,3 ,4 ]
Bianchi, Giada [2 ,5 ]
Taylor, Alexandra [1 ,2 ]
Benz, Dominik C. [1 ,2 ]
Robertson, Matthew [3 ,4 ]
Kijewski, Marie Foley [1 ]
Jerosch-Herold, Michael [3 ,4 ]
Kwong, Raymond Y. [3 ,4 ]
Ruberg, Frederick L. [6 ,7 ]
Liao, Ronglih [8 ]
Carli, Marcelo F. Di [1 ,3 ,4 ]
Falk, Rodney H. [2 ]
Dorbala, Sharmila [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Dept Radiol, Div Nucl Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Div Cardiol, Cardiac Amyloidosis Program, Boston, MA USA
[3] Brigham & Womens Hosp, CV Imaging Program, Cardiovasc Div, Boston, MA USA
[4] Brigham & Womens Hosp, Dept Radiol, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA
[6] Boston Univ, Chobanian & Avedisian Sch Med, Amyloidosis Ctr, Boston, MA USA
[7] Boston Univ, Chobanian & Avedisian Sch Med, Boston Med Ctr, Dept Med,Sect Cardiovasc Med, Boston, MA 02215 USA
[8] Stanford Univ, Amyloidosis Program, Stanford, CA USA
关键词
light-chain (AL) amyloidosis; cardiomyopathy; F-18-florbetapir; adverse outcomes; positron emission tomography (PET); mediation analysis; POSITRON-EMISSION-TOMOGRAPHY; CARDIAC AMYLOIDOSIS; QUANTIFICATION; DYSFUNCTION; PET;
D O I
10.1016/j.jcmg.2024.05.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Positron emission tomography/computed tomography (PET/CT) with F-18-florbetapir, a novel amyloid-targeting radiotracer, can quantify left ventricular (LV) amyloid burden in systemic light-chain (AL) amyloidosis. However, its prognostic value is not known. OBJECTIVES The authors' aim was to evaluate the prognostic value of LV amyloid burden quantified by F-18-florbetapir PET/CT, and to identify mechanistic pathways mediating its association with outcomes. METHODS A total of 81 participants with newly diagnosed AL amyloidosis underwent F-18-florbetapir PET/CT imaging. Amyloid burden was quantified using F-18-florbetapir LV uptake as percent injected dose. The Mayo stage for AL amyloidosis was determined using troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and free light chain levels. Major adverse cardiac events (MACE) were defined as all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months. RESULTS Among participants (median age, 61 years; 57% males), 36% experienced MACE, increasing from 7% to 63% across tertiles of LV amyloid burden (P < 0.001). LV amyloid burden was associated with MACE (HR: 1.46; 95% CI: 1.16-1.83; P = 0.001). However, this association became nonsignificant when adjusted for Mayo stage. In mediation analysis, the association between LV amyloid burden and MACE was mediated by NT-proBNP (P < 0.001), a marker of cardiomyocyte stretch and heart failure, and a component of Mayo stage. CONCLUSIONS In this first study to link cardiac F-18-florbetapir uptake to subsequent outcomes, LV amyloid burden estimated by percent injected dose predicted MACE in AL amyloidosis. This effect was not independent of Mayo stage and was mediated primarily through NT-proBNP. These findings provide novel insights into the mechanism linking myocardial amyloid deposits to MACE. (c) 2024 by the American College of Cardiology Foundation.
引用
收藏
页码:911 / 922
页数:12
相关论文
共 50 条
  • [41] Intramural coronary light-chain amyloidosis and left ventricular assist device implantation
    Kamdar, Forum
    Tan, Carmela D.
    Rodriguez, E. Rene
    Moazami, Nader
    Hanna, Mazen
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (10): : 1163 - 1164
  • [42] Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography
    Dorbala, Sharmila
    Vangala, Divya
    Semer, James
    Strader, Christopher
    Bruyere, John R., Jr.
    Di Carli, Marcelo F.
    Moore, Stephen C.
    Falk, Rodney H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (09) : 1652 - 1662
  • [43] Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis
    Perlini, Stefano
    Salinaro, Francesco
    Musca, Francesco
    Mussinelli, Roberta
    Boldrini, Michele
    Raimondi, Ambra
    Milani, Paolo
    Foli, Andrea
    Cappelli, Francesco
    Perfetto, Federico
    Palladini, Giovanni
    Rapezzi, Claudio
    Merlini, Giampaolo
    JOURNAL OF HYPERTENSION, 2014, 32 (05) : 1121 - 1131
  • [44] Prognostic Value of Iodine-123-Metaiodobenzylguanidine Scintigraphy in Light-Chain Amyloidosis
    Nicol, Martin
    Baudet, Mathilde
    Cescau, Arthur
    Harel, Stephanie
    Royer, Bruno
    Sarda-Mantel, Laure
    Cohen-Solal, Alain
    Arnulf, Bertrand
    Logeart, Damien
    CIRCULATION-CARDIOVASCULAR IMAGING, 2019, 12 (11)
  • [45] Prognostic value of left atrial mechanics in cardiac light-chain amyloidosis with preserved ejection fraction: a cohort study
    Xiao-hang Liu
    Jia-yu Shi
    Ding-ding Zhang
    Fu-wei Jia
    Xue Lin
    Yan-lin Zhu
    Jun-ling Zhuang
    Li-gang Fang
    Wei Chen
    BMC Cardiovascular Disorders, 22
  • [46] Prognostic value of left atrial mechanics in cardiac light-chain amyloidosis with preserved ejection fraction: a cohort study
    Liu, Xiao-hang
    Shi, Jia-yu
    Zhang, Ding-ding
    Jia, Fu-wei
    Lin, Xue
    Zhu, Yan-lin
    Zhuang, Jun-ling
    Fang, Li-gang
    Chen, Wei
    BMC CARDIOVASCULAR DISORDERS, 2022, 22 (01)
  • [47] Visualization of Amyloid Arthropathy in Light-Chain Systemic Amyloidosis on F-18 FDG PET/CT Scan
    Mekinian, Arsene
    Ghrenassia, Etienne
    Pop, Gabriel
    Roberts, Sarah
    Prendki, Virginie
    Stirnemann, Jerome
    Weinmann, Pierre
    Fain, Olivier
    CLINICAL NUCLEAR MEDICINE, 2011, 36 (01) : 52 - 53
  • [48] Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography
    Sharmila Dorbala
    Divya Vangala
    James Semer
    Christopher Strader
    John R. Bruyere
    Marcelo F. Di Carli
    Stephen C. Moore
    Rodney H Falk
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 1652 - 1662
  • [49] 18F-florbetapir uptake in a primary intraosseous haemangioma displayed in a cerebral PET/CT
    Sanchez-Vano, R.
    Prado-Wohlwend, S.
    Sopena-Novales, P.
    Uruburu-Garcia, E.
    Monedero-Picazo, M. D.
    Martinez-Carsi, C.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2018, 37 (01): : 59 - 60
  • [50] A novel approach for semi-quantitative estimation of global amyloid uptake utilizing 18F-florbetapir (florbetapir F 18) and positron emission tomography
    Saha, Krishnendu
    Romanowicz, Grzegorz
    Joshi, Abhinay
    Pontecorvo, Michael
    Burns, Jason
    Carpenter, Alan
    Skovronsky, Daniel
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51